Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHL
Andrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.
Andrew M. Evens, DO, MSc, director of the Lymphoma Program and associate director for Clinical Services at the Rutgers Cancer Institute of New Jersey, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma (cHL) were treated with the combination of brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (A+AVD).
The primary endpoint was progression-free survival (PFS). The trial results demonstrated an absolute improvement of 5% in PFS by independent review panel and 6.6% by investigator. The addition may be small, Evens notes, but it means that 20 patients need to be treated with the addition of brentuximab vedotin to prevent a modified PFS in 1 patient.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
